5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Well differentiated neuroendocrine carcinomas have low proliferative activity and
conventional chemotherapy is not recommended. Metronomic chemotherapy, i.e. the frequent
administration of cytotoxic drugs at low doses, has demonstrated antiangiogenetic properties.
Since well differentiated NE carcinomas are highly vascular, there is a rationale for testing
metronomic chemotherapy in this clinical setting.
A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU)
infusion plus long-acting release (LAR) octreotide for patients with neuroendocrine
carcinoma.